Lobe-specific Lymph Node Dissection for Clinical Stage IA Non–small-cell Lung Cancer: What do we know?

Abstract

We read the article by Zhao et al.1 with great interest. The study included 546 patients with stage IA solid-dominant, non–small-cell lung cancer (NSCLC) who underwent lobe-specific lymph node dissection (L-SLND) (100 patients) or systematic lymph node dissection (SLND) (446 patients). Their results showed that L-SLND was similar to SLND regarding survival rate, recurrence rate, and perioperative recovery, but had significant advantages in reducing postoperative complications over SLND. Therefore the authors suggested that L-SLND may be more suitable for patients with clinical stage IA solid-dominant NSCLC.